Anixa Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
SAN JOSE, Calif., Sept. 8, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that Dr. Amit Kumar, Anixa's Chief Executive Officer, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021.
During the presentation, Dr. Kumar will provide an overview of Anixa's business and highlight recent corporate achievements, including the recent FDA clearance to proceed with clinical trials of its CAR-T based ovarian cancer therapeutic program, as well as anticipated milestones in its breast cancer vaccine clinical trials. Company management will also be available to participate in online one-on-one meetings with conference attendees.
Details of Anixa's presentation are as follows:
Event: H.C. Wainwright 23rd Annual Global Investment Conference
Date & Time: On demand, beginning 7:00 a.m. ET, Monday, September 13, 2021
An archive of the webcast will remain available for 90 days after the event.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301371197.html
SOURCE Anixa Biosciences, Inc.
Released September 8, 2021
Sign up for email Updates
Be The First to Receive Breaking NewsSign Up Now